Glycopyrronium bromide is a new long-acting anticholinergic drug for the treatment of COPD
https://doi.org/10.21518/2079-701X-2014-16-6-11
Abstract
Glycopyrronium is a new powerful quick-acting anticholinergic bronchodilator for the treatment of chronic obstructive pulmonary disease. Glycopyrronium is powder in Breezhaler® inhalation device. The review tells about phase III clinical trials demonstrating the positive effect of glycopyrronium on lung function, symptoms of the disease, exercise tolerance, frequency of severe and moderate COPD exacerbations and quality of life of patients. The drug showed good tolerability and high cardiac safety in a long-term period.
About the Authors
S. N. Avdeev
Scientific Research Institute of Pulmonology, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
S. Y. Chikina
Scientific Research Institute of Pulmonology, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
References
1. Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. The 2014 report is available on www.goldcopd.com.
2. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. EurRespir J, 2004, 23: 932-946.
3. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet, 2007, 370: 741-50.
4. Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med, 2010, 16: 97-105.
5. Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron ObstructPulmon Dis, 2012, 7: 729-741.
6. Ulrik CS. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int J Chron Obstruct Pulmon Dis, 2012, 7: 673-678.
7. Barnes PJ. Theoretical aspects of anticholinergic treatment. In: Gross N (ed). Anticholinergic therapy in obstructive lung disease. Franklin Scientific Publication, London, 1993: 88-104.
8. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, Hardman JG, Limbird LE, Molinoff PB, et al. (Eds), Ninth edition, McGraw-Hill. New York, 1996, p. 141.
9. Sykes DA, Dowling MR, Leighton-Davies J, et al. The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium.J.Pharmacol.Exp Ther, 2012, 343: 520-528.
10. Bartels C, Looby M, Sechaud R, Kaiser G. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modeling approach. Br. J Clin Pharmacol, 2013. doi: 10.1111/bcp.12118.
11. Arievich H, Overend T, Renard D, et al. Glycopyrronium, an inhaled long-acting muscarinic antagonist: a dose-ranging study in patients with COPD. BMC Pulm Med, 2012, 12: 74.
12. Chapman KR, Fogarty CM, Peckitt C, et al. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis, 2011, 6: 353-363.
13. D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res, 2011, 12: 156.
14. Kerwin E, H bert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J, 2012, 40: 1106-1114.
15. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis, 2012, 7: 503-513.
16. Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respiratory Research, 2013, 14: 112.
17. Vincken W, Aumann J, Chen H. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study International Journal of COPD, 2014, 9: 215-228.
Review
For citations:
Avdeev SN, Chikina SY. Glycopyrronium bromide is a new long-acting anticholinergic drug for the treatment of COPD. Meditsinskiy sovet = Medical Council. 2014;(16):6-11. (In Russ.) https://doi.org/10.21518/2079-701X-2014-16-6-11
Views:
1468
Email this article 